TABLE 1. Estrogenic Activities of the Test Compounds in the In Vivo Uterotrophic Bioassay, U2OS ERα CALUX Assay, Yeast Estrogen Bioassay, and ERα Coregulator Binding Assay.
| Compound | CAS no. | Uterotrophic assay log RPa | U2OS ERα CALUX bioassay | Yeast estrogen bioassay | ERα coregulator binding assay | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| EC50 (M) | log REP | RTA (%) | EC50 (M) | log REP | RTA (%) | Median EC50e/IC50f (M) | log RBP | |||
| Estradiol | 50-28-2 | 2.0 | 8.8 × 10−12 | 2.0 | 100 | 8.7 × 10−10 | 2.0 | 100 | 7.5 × 10−9e | 2.0 |
| Equilin | 474-86-2 | 1.7 | 6.5 × 10−11 | 1.1 | 95 | 8.7 × 10−09 | 1.0 | 105 | 3.4 × 10−8e | 1.3 |
| Mestranol | 72-33-3 | 2.0 | 3.2 × 10−10 | 0.4 | 84 | 7.9 × 10−09 | 1.0 | 88 | 5.1 × 10−7e | 0.2 |
| DES-ME | 7773-60-6 | 1.9 | 2.4 × 10−10 | 0.6 | 88 | 1.8 × 10−09 | 1.7 | 94 | 1.7 × 10−7e | 0.6 |
| Bisphenol A | 80-05-7 | −1.6 | 2.7 × 10−07 | −2.5 | 136 | 2.0 × 10−05 | −2.4 | 76 | — | −5.0 |
| Bisphenol B | 77-40-7 | +b | 1.2 × 10−07 | −2.1 | 144 | 5.0 × 10−06 | −1.8 | 87 | 3.2 × 10−6f | na |
| Bisphenol C1 | 14868-03-2 | NAc | 2.7 × 10−08 | −1.5 | 133 | 2.2 × 10−07 | −0.4 | 93 | 2.7 × 10−8f | na |
| Bisphenol C2 | 79-97-0 | NA | 2.1 × 10−07 | −2.4 | 125 | 4.5 × 10−06 | −1.6 | 87 | 7.4 × 10−4f | na |
| Butyl paraben | 94-26-8 | + | 2.9 × 10−06 | −3.5 | 256 | 5.1 × 10−06 | −1.8 | 86 | — | −5.0 |
| Atrazine | 1912-24-9 | −5.0d | —b | −5.0 | 1 | — | −5.0 | 1 | — | −5.0 |
| Vinclozolin | 50471-44-8 | −5.0 | — | −5.0 | 8 | — | −5.0 | 4 | — | −5.0 |
aMedian relative potency values based on the uterotrophic assay in mouse or rat, derived from EDKB (NCTR, USA) (Ding et al., 2010). Estradiol is used as a reference chemical and is defined to have a relative potency of 100 (log RP = 2.0).
b+ = positive; − = negative.
cNA = not available; na = not applicable.
dA cut-off value of −5.0 is listed for compounds showing no effect.